Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.

Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr.

Science. 1995 Sep 8;269(5229):1444-6.

PMID:
7660130
2.

Inhibition of transcription elongation by the VHL tumor suppressor protein.

Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD.

Science. 1995 Sep 8;269(5229):1402-6.

PMID:
7660122
3.

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr.

Hum Mol Genet. 2001 May 1;10(10):1019-27.

4.

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.

Hum Mol Genet. 2001 May 1;10(10):1029-38.

5.

Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.

Tsuchiya MI, Okuda H, Takaki Y, Baba M, Hirai S, Ohno S, Shuin T.

Oncol Rep. 2005 Jun;13(6):1033-41.

PMID:
15870918
6.

Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.

Schoenfeld AR, Davidowitz EJ, Burk RD.

Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8507-12.

7.

The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.

Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER.

Oncogene. 2001 Aug 16;20(36):5067-74.

8.
9.
10.

Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.

Takagi Y, Pause A, Conaway RC, Conaway JW.

J Biol Chem. 1997 Oct 24;272(43):27444-9.

11.

Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.

Lee S, Neumann M, Stearman R, Stauber R, Pause A, Pavlakis GN, Klausner RD.

Mol Cell Biol. 1999 Feb;19(2):1486-97.

13.

The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.

Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2156-61.

14.

Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.

Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G.

J Biol Chem. 2002 Feb 15;277(7):4656-62. Epub 2001 Dec 5.

15.

Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.

Bonicalzi ME, Groulx I, de Paulsen N, Lee S.

J Biol Chem. 2001 Jan 12;276(2):1407-16.

16.

Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.

Feldman DE, Thulasiraman V, Ferreyra RG, Frydman J.

Mol Cell. 1999 Dec;4(6):1051-61.

17.

Tumour suppression by the human von Hippel-Lindau gene product.

Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr.

Nat Med. 1995 Aug;1(8):822-6.

PMID:
7585187
18.

The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.

Pioli PA, Rigby WF.

J Biol Chem. 2001 Oct 26;276(43):40346-52. Epub 2001 Aug 21.

19.

The von Hippel-Lindau tumor suppressor gene and kidney cancer.

Kaelin WG Jr.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. Review.

20.

Comparative sequence analysis of the VHL tumor suppressor gene.

Woodward ER, Buchberger A, Clifford SC, Hurst LD, Affara NA, Maher ER.

Genomics. 2000 May 1;65(3):253-65.

PMID:
10857749
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk